IL180706A0 - Pharmaceutical dosage forms including rasagiline - Google Patents
Pharmaceutical dosage forms including rasagilineInfo
- Publication number
- IL180706A0 IL180706A0 IL180706A IL18070607A IL180706A0 IL 180706 A0 IL180706 A0 IL 180706A0 IL 180706 A IL180706 A IL 180706A IL 18070607 A IL18070607 A IL 18070607A IL 180706 A0 IL180706 A0 IL 180706A0
- Authority
- IL
- Israel
- Prior art keywords
- dosage forms
- pharmaceutical dosage
- forms including
- rasagiline
- including rasagiline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59135904P | 2004-07-26 | 2004-07-26 | |
US60624104P | 2004-09-01 | 2004-09-01 | |
PCT/US2005/026517 WO2006014973A2 (en) | 2004-07-26 | 2005-07-26 | Pharmaceutical dosage forms including rasagiline |
Publications (1)
Publication Number | Publication Date |
---|---|
IL180706A0 true IL180706A0 (en) | 2007-06-03 |
Family
ID=35787777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL180706A IL180706A0 (en) | 2004-07-26 | 2007-01-15 | Pharmaceutical dosage forms including rasagiline |
Country Status (7)
Country | Link |
---|---|
US (1) | US20060018957A1 (en) |
EP (1) | EP1778196A4 (en) |
JP (1) | JP2008507586A (en) |
AU (1) | AU2005269416B2 (en) |
CA (1) | CA2574925A1 (en) |
IL (1) | IL180706A0 (en) |
WO (1) | WO2006014973A2 (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2588780T3 (en) | 2002-11-15 | 2016-11-04 | Teva Pharmaceutical Industries Limited | Use of rasagiline with or without riluzole for the treatment of amyotrophic lateral sclerosis |
RU2389482C2 (en) * | 2004-11-24 | 2010-05-20 | Тева Фармасьютикал Индастриз, Лтд. | Rasagiline compositions degrading in mouth cavity |
RS52867B (en) * | 2005-02-17 | 2013-12-31 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
MX2007010233A (en) * | 2005-02-23 | 2007-11-07 | Teva Pharma | Rasagiline formulations of improved content uniformity. |
EP1954667B1 (en) * | 2005-11-17 | 2017-02-08 | Teva Pharmaceutical Industries Ltd | Methods for isolating propargylated aminoindans |
US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
WO2007098264A2 (en) | 2006-02-21 | 2007-08-30 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
CA2646250A1 (en) * | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
US7807715B2 (en) * | 2006-06-09 | 2010-10-05 | Ucb Pharma Gmbh | Pharmaceutical compositions comprising fesoterodine |
EP1892233A1 (en) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | New salts of the active component rasagiline |
JP5623081B2 (en) * | 2006-12-14 | 2014-11-12 | テバ ファーマシューティカル インダストリーズ リミティド | Crystalline solid rasagiline base |
AU2007334493B2 (en) * | 2006-12-14 | 2010-12-02 | Teva Pharmaceutical Industries, Ltd. | Tannate salt of rasagiline |
US20100303901A1 (en) * | 2007-04-26 | 2010-12-02 | Eyal Shimoni | Oral delivery of proteins and peptides |
EP1987816A1 (en) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate of a rasagiline salt with a water-soluble inactive ingredient |
EP2194780A4 (en) * | 2007-09-05 | 2010-10-27 | Teva Pharma | Method of treating glaucoma using rasagiline |
US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
NZ586025A (en) * | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
WO2009151594A1 (en) * | 2008-06-10 | 2009-12-17 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
JP2011522892A (en) * | 2008-06-13 | 2011-08-04 | テバ ファーマシューティカル インダストリーズ リミティド | Rasagiline for relieving Parkinson's disease |
BRPI0909997A2 (en) | 2008-06-19 | 2015-10-27 | Teva Pharma | crystalline r (+) - n-propargyl-1-aminoindan, pharmaceutical composition, drying process solid r (+) - n-propargyl-1-aminoindan, preparation of a pharmaceutical composition, validated batch production process of a drug product containing crystalline r (+) - n-propargyl-1-aminoindane and at least one pharmaceutically acceptable carrier for delivery and prudential process of crystalline r (+) - n-propargyl-1-aminoindane |
CA2727021A1 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
US20110172249A1 (en) | 2008-09-03 | 2011-07-14 | Takeda Pharmaceutical Company Limted | Method for improving absorbability of preparation, and preparation having improved absorbability |
DE102008064061A1 (en) * | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Solid composition with the active ingredient rasagiline |
US20100189790A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
EP2218444A3 (en) | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
CN102341104A (en) * | 2009-03-05 | 2012-02-01 | 桑多斯股份公司 | Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, methanesulfonate |
WO2010111264A2 (en) * | 2009-03-24 | 2010-09-30 | Dr. Reddy's Laboratories Ltd. | Rasagiline formulations |
JP2012532843A (en) | 2009-07-09 | 2012-12-20 | ラティオファーム ゲーエムベーハー | Rasagiline salt and preparation thereof |
AU2010341499A1 (en) | 2009-12-22 | 2012-08-09 | Teva Pharmaceutical Industries Ltd. | 3-keto-N-propargyl-1-aminoindan |
EP3517103A1 (en) * | 2010-02-03 | 2019-07-31 | Pharma Two B Ltd. | Extended release formulations of rasagiline and uses thereof |
US9205577B2 (en) * | 2010-02-05 | 2015-12-08 | Allergan, Inc. | Porogen compositions, methods of making and uses |
US9138309B2 (en) | 2010-02-05 | 2015-09-22 | Allergan, Inc. | Porous materials, methods of making and uses |
US8920840B2 (en) | 2010-04-30 | 2014-12-30 | Takeda Pharmaceutical Company Limited | Enteric tablet |
EA030433B1 (en) | 2010-04-30 | 2018-08-31 | Такеда Фармасьютикал Компани Лимитед | Enteric tablet |
US11202853B2 (en) * | 2010-05-11 | 2021-12-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
EP2389927A1 (en) * | 2010-05-30 | 2011-11-30 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of rasagiline |
AU2011282716A1 (en) | 2010-07-27 | 2013-03-14 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
CA2806740A1 (en) | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
JP2014503480A (en) * | 2010-10-26 | 2014-02-13 | テバ ファーマシューティカル インダストリーズ リミティド | Deuterium-rich rasagiline |
AU2012323349A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | R(+)-N-formyl-propargyl-aminoindan |
BR112014008552A2 (en) | 2011-10-10 | 2017-04-18 | Teva Pharma | r (+) - n-methylpropargylaminoindane |
US9504657B2 (en) | 2012-01-12 | 2016-11-29 | Pharmatwob Ltd. | Fixed dose combination therapy of Parkinson's disease |
US20150079187A1 (en) * | 2012-01-12 | 2015-03-19 | Pharma Two B Ltd. | Fixed dose combination therapy of parkinson's disease |
JP2015529196A (en) | 2012-08-17 | 2015-10-05 | テバ ファーマシューティカル インダストリーズ リミティド | Rasagiline parenteral formulation |
ES2524865T1 (en) * | 2013-02-06 | 2014-12-15 | Galenicum Health S.L. | Stable pharmaceutical compositions in the form of immediate-release tablets |
ES2502140T1 (en) * | 2013-02-06 | 2014-10-02 | Galenicum Health S.L. | Rasagiline hemitartrate immediate-release tablets |
IN2013MU01782A (en) * | 2013-05-20 | 2015-06-26 | Cadila Healthcare Ltd |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
IL112819A (en) * | 1991-10-16 | 2001-11-25 | Teva Pharma | Fluorinated 1-aminoindan compounds and a process for their preparation |
IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
DE69732984T2 (en) * | 1996-12-18 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | AMINOINDANDERIVATE |
AU2472499A (en) * | 1998-01-27 | 1999-08-09 | Thomas N. Thomas | Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl |
US20020137786A1 (en) * | 1998-02-12 | 2002-09-26 | William G. Tatton | Deprenyl compounds to treat viral infections and reduce tissue damage associated therewith |
US6139875A (en) * | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6123968A (en) * | 1999-03-23 | 2000-09-26 | Mendez; Alejandro | Composition for extending shelf life for fresh fruits and vegetables without the use of refrigeration |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
PL370793A1 (en) | 2001-07-04 | 2005-05-30 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
NZ534104A (en) * | 2001-12-24 | 2007-03-30 | Teva Pharma | Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material |
US20040010038A1 (en) * | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
JP2005525377A (en) * | 2002-03-04 | 2005-08-25 | サマセット ファーマシューティカルズ, インコーポレイテッド | Method for prevention and treatment of peripheral neuropathy by administration of desmethyl selegiline |
US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
AU2003288902A1 (en) * | 2002-09-06 | 2004-04-08 | Genteric, Inc. | Microcapsules and methods of use |
ES2588780T3 (en) * | 2002-11-15 | 2016-11-04 | Teva Pharmaceutical Industries Limited | Use of rasagiline with or without riluzole for the treatment of amyotrophic lateral sclerosis |
US7735024B2 (en) * | 2003-10-29 | 2010-06-08 | Intel Corporation | Methods and apparatus to provide a handheld pointer-based user interface |
US20090111892A1 (en) * | 2004-11-24 | 2009-04-30 | Shulamit Patashnik | Rasagiline Orally Disintegrating Compositions |
MX2007010233A (en) * | 2005-02-23 | 2007-11-07 | Teva Pharma | Rasagiline formulations of improved content uniformity. |
EP1954667B1 (en) * | 2005-11-17 | 2017-02-08 | Teva Pharmaceutical Industries Ltd | Methods for isolating propargylated aminoindans |
US7572834B1 (en) * | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
WO2007098264A2 (en) * | 2006-02-21 | 2007-08-30 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
CA2646250A1 (en) * | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
EP1892233A1 (en) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | New salts of the active component rasagiline |
AU2007334493B2 (en) * | 2006-12-14 | 2010-12-02 | Teva Pharmaceutical Industries, Ltd. | Tannate salt of rasagiline |
JP5623081B2 (en) * | 2006-12-14 | 2014-11-12 | テバ ファーマシューティカル インダストリーズ リミティド | Crystalline solid rasagiline base |
EP1987816A1 (en) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate of a rasagiline salt with a water-soluble inactive ingredient |
EP2194780A4 (en) * | 2007-09-05 | 2010-10-27 | Teva Pharma | Method of treating glaucoma using rasagiline |
US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
NZ586025A (en) * | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
WO2009151594A1 (en) * | 2008-06-10 | 2009-12-17 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
JP2011522892A (en) * | 2008-06-13 | 2011-08-04 | テバ ファーマシューティカル インダストリーズ リミティド | Rasagiline for relieving Parkinson's disease |
BRPI0909997A2 (en) * | 2008-06-19 | 2015-10-27 | Teva Pharma | crystalline r (+) - n-propargyl-1-aminoindan, pharmaceutical composition, drying process solid r (+) - n-propargyl-1-aminoindan, preparation of a pharmaceutical composition, validated batch production process of a drug product containing crystalline r (+) - n-propargyl-1-aminoindane and at least one pharmaceutically acceptable carrier for delivery and prudential process of crystalline r (+) - n-propargyl-1-aminoindane |
CA2727021A1 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
WO2011012140A2 (en) * | 2008-07-11 | 2011-02-03 | Synthon Bv | Polymorphs of rasagiline hydrochloride |
US20100029987A1 (en) * | 2008-07-29 | 2010-02-04 | Dipharma Francis S.R.I. | Crystalline Form of Rasagiline and Process for the Preparation Thereof |
US20100189790A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
-
2005
- 2005-07-26 CA CA002574925A patent/CA2574925A1/en not_active Abandoned
- 2005-07-26 AU AU2005269416A patent/AU2005269416B2/en not_active Ceased
- 2005-07-26 EP EP05782669A patent/EP1778196A4/en not_active Withdrawn
- 2005-07-26 WO PCT/US2005/026517 patent/WO2006014973A2/en active Application Filing
- 2005-07-26 JP JP2007523735A patent/JP2008507586A/en active Pending
- 2005-07-26 US US11/190,623 patent/US20060018957A1/en not_active Abandoned
-
2007
- 2007-01-15 IL IL180706A patent/IL180706A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1778196A4 (en) | 2008-12-17 |
EP1778196A2 (en) | 2007-05-02 |
US20060018957A1 (en) | 2006-01-26 |
AU2005269416B2 (en) | 2011-07-28 |
WO2006014973A3 (en) | 2006-04-13 |
JP2008507586A (en) | 2008-03-13 |
WO2006014973A2 (en) | 2006-02-09 |
AU2005269416A1 (en) | 2006-02-09 |
CA2574925A1 (en) | 2006-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL180706A0 (en) | Pharmaceutical dosage forms including rasagiline | |
IL251539A0 (en) | Unitary pharmaceutical dosage form | |
IL185390A (en) | Solid pharmaceutical dosage formulation | |
IL182614A0 (en) | Pharmaceutical compounds | |
GB0419849D0 (en) | Pharmaceutical combination | |
IL181229A0 (en) | Noncardiotoxic pharmaceutical compounds | |
GB0427455D0 (en) | Dosage forms | |
EP1948138A4 (en) | Segmented pharmaceutical dosage forms | |
ZA200803152B (en) | Oramucosal pharmaceutical dosage form | |
GB0423964D0 (en) | Dosage form | |
GB0512453D0 (en) | Dosage unit | |
ZA200605666B (en) | Solid dosage form | |
ZA200707910B (en) | Contraceptive pharmaceutical preparation | |
EP1716865A4 (en) | Paraoxonase-containing pharmaceutical preparation | |
GB0428554D0 (en) | Pharmaceutical compounds | |
GB0424742D0 (en) | Pharmaceutical compounds | |
GB0417777D0 (en) | Pharmaceutical combination | |
GB0424994D0 (en) | Dosage form | |
GB0411047D0 (en) | Dosage form | |
GB0411667D0 (en) | Controlled-release dosage form | |
GB0411669D0 (en) | Controlled-release dosage form | |
EP1745780A4 (en) | Medicinal preparation | |
GB0418270D0 (en) | Pharmaceutical formulation | |
GB0422111D0 (en) | Pharmaceutical formulation | |
GB0418567D0 (en) | Pharmaceutical combination |